Annexin Pharmaceuticals AB
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
ANNX | ST
Overview
Corporate Details
- ISIN(s):
- SE0009664154
- LEI:
- 5493000JP703HGPJEX27
- Country:
- Sweden
- Address:
- KAMMAKARGATAN 48, 111 60 Stockholm
- Website:
- https://annexinpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on the therapeutic protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant human Annexin A5 that targets phosphatidylserine (PS), a lipid exposed on the surface of stressed or damaged cells. By binding to PS, ANXV acts as a cell protector and immunomodulator, counteracting tissue injury and regulating immune responses. The company's primary focus is on developing ANXV for indications with significant unmet medical needs, including Retinal Vein Occlusion (RVO), for which it is currently in Phase 2 clinical trials, and oncology. ANXV has potential as a first-in-class treatment across a broad range of vascular, inflammatory, and cancerous diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
